Cytek: jury finds for it on three of four claims in Beckman Coulter patent case
On August 21, 2026, a Delaware federal jury returned a verdict in patent infringement action brought by Beckman Coulter against Cytek Biosciences. The jury found noninfringement and invalidity on three of four asserted claims, but found infringement under the doctrine of equivalents on one claim and awarded $20 million in lost profits and $36.11 million in royalties. The company plans post-verdict motions and may appeal, and says the verdict does not require changes to its current products or operations.
Key points
- Jury found noninfringement and invalidity on three of the four asserted patent claims.
- On the remaining claim, jury found no literal infringement but found infringement under the doctrine of equivalents.
- Past damages awarded: $20 million in lost profits and $36.11 million in royalties.
- Company intends to pursue post-verdict motions and may appeal to the Federal Circuit; it says its products remain available.
The filing
Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 24, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.